Lipids and Cholesterol

Latest

Effects of Sex-Dependent On-Treatment LDL Diferences on CVD Risk

Effects of Sex-Dependent On-Treatment LDL Diferences on CVD Risk

Women experienced the same CV benefits in statin trials, despite having slightly elevated on-treatment LDL cholesterol.

Incident CHD Risk Elevated With High Triglycerides, Low HDL

Incident CHD Risk Elevated With High Triglycerides, Low HDL

Risk of both ischemic stroke and coronary heart disease was elevated with high triglycerides and low high-density lipoprotein cholesterol.

Are Extremely Low LDL Cholesterol Levels Safe?

Are Extremely Low LDL Cholesterol Levels Safe?

Low levels of low-density lipoprotein cholesterol appear to be well tolerated on alirocumab therapy.

How Low is Too Low?: Safety and Tolerability of Extremely Low LDL Examined

How Low is Too Low?: Safety and Tolerability of Extremely Low LDL Examined

Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.

Too Few Young Adults Are Prescribed Needed Statins

Too Few Young Adults Are Prescribed Needed Statins

Too few American young adults are receiving needed statin medications, according to findings published in JAMA Cardiology.

Fenofibrate Therapy Beneficial in Diabetes With Dyslipidemia

Fenofibrate Therapy Beneficial in Diabetes With Dyslipidemia

Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.

Oxidative Stress Associated With Metabolic Syndrome

Oxidative Stress Associated With Metabolic Syndrome

Oxidized low-density lipoprotein (ox-LDL) as a proxy for oxidative stress is associated with metabolic syndrome and its components.

Total, LDL Cholesterol Levels Decreasing in the United States

Total, LDL Cholesterol Levels Decreasing in the United States

Healthier diets may be a factor in the ongoing decline in cholesterol levels for Americans.

Disparities in Dyslipidemia Testing in HIV

Disparities in Dyslipidemia Testing in HIV

Women and minorities with HIV are less frequently tested for dyslipidemia, according to a new study from IDWeek 2016.

ORION-1: PCSK9 Synthesis Inhibitor May Reduce LDL Cholesterol in High-Risk Patients

ORION-1: PCSK9 Synthesis Inhibitor May Reduce LDL Cholesterol in High-Risk Patients

A mean 51% reduction in LDL cholesterol was seen in the group assigned to the 300 mg dose of inclisiran.

Sign Up for Free e-Newsletters